Analyzing the expression of breast cancer stem cell markers CD44 and CD24, we found that over 95% of control MDA-MB-231 cells express CD44 but not CD24, thus exhibiting a breast cancer stem-like cell phenotype. This evidence concerns the gene CD24 and breast carcinoma.